Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute reports developments in value-based community oncology care, combining oncology and hematology services with specialty pharmacy, patient services, clinical trials, transfusions, and related care models. Its updates center on operating results, specialty pharmacy volume, gross profit and cash flow trends, and the performance of capitated and Medicare Advantage payor relationships.
Company news also covers participation in CMS oncology payment models, contract expansion across community oncology markets, clinical pathway and provider engagement initiatives, investor conference appearances, and governance or compliance leadership changes. The business operates through Specialty Pharmacy, Patient Services, and Clinical Trials and Other segments.
Starling Oncology (Nasdaq: STLN), formerly The Oncology Institute ("TOI"), announced a corporate rebrand to “Starling Oncology, Inc.™.” The company’s common stock will begin trading on Nasdaq under the new ticker symbol STLN on August 4, 2026, replacing “TOI.” According to the company, the new name reflects its evolution into an integrated oncology platform, while patients, payers, and providers are expected to experience no changes to phone numbers, portals, or points of contact and no disruption to care during the transition.
The Oncology Institute (NASDAQ: TOI) will release its second quarter 2026 financial results on Thursday, August 6, 2026, followed by a conference call at 5:00 p.m. Eastern Time. Investors can access the call via domestic and international dial-in numbers or through a live webcast on the company’s investor relations website. A telephone replay and webcast replay will be available until 11:59 p.m. Eastern Time on August 20, 2026.
The Oncology Institute (NASDAQ: TOI) completed a strategic refinancing, repaying its $86 million senior secured convertible note with Deerfield Partners. The repayment used a new $75 million OrbiMed term loan maturing in 2031 plus about $11 million of cash, aiming to boost liquidity, flexibility, and extend debt maturities without raising equity.
The Oncology Institute (NASDAQ: TOI) announced that Chief Medical Officer Yale D. Podnos, MD, MPH, FACS, will speak at the APG Spring Conference on May 28, 2026, in San Diego.
He will join a panel on Engaging More Specialists in Value-Based Care, sharing oncology-focused insights on outcomes, costs, care quality, and patient safety.
The Oncology Institute (NASDAQ:TOI) announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the B. Riley Securities Institutional Investor Conference in Marina Del Rey, CA, on May 21, 2026.
A fireside chat is scheduled from 9:00–9:40 a.m. PT and will be available via webcast on the company’s investor relations website.
The Oncology Institute (NASDAQ: TOI) reported Q1 2026 results for the quarter ended March 31, 2026. Consolidated revenue was $147.4 million, up 41.2% year-over-year; gross profit was $23.3 million, up 35.2%.
Q1 net loss narrowed to $2.5 million from $19.6 million; adjusted EBITDA improved to $(2.4) million. Specialty pharmacy revenue rose 78% and the company expects 200,000 Medicare Advantage lives in Florida effective July 1, 2026. 2026 guidance largely unchanged; free cash flow range updated to $5–$15 million.
The Oncology Institute (NASDAQ: TOI) will release first quarter 2026 financial results on Thursday, May 7, 2026, followed by a conference call the same day at 5:30 p.m. ET. A live dial-in, international numbers, and a simultaneous webcast via the Investor Relations website are provided.
A replay will be available two hours after the call through Thursday, May 21, 2026 using the provided replay numbers and passcode 11161701.
The Oncology Institute (NASDAQ: TOI) achieved $1.8 million in Medicare savings during CMS Enhancing Oncology Model Performance Period 3, equal to more than $6,400 per patient episode. This improves on Performance Period 2 savings of $1.1 million ($3,500+ per episode).
TOI earned maximum quality scores on avoidable emergency department visits and hospital admissions for a second consecutive period, driven by its High-Value Cancer Care program, care navigation, Health Care Coach symptom monitoring, and 24/7 symptom management.
The Oncology Institute (NASDAQ: TOI) announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the 25th Annual Needham Healthcare Conference on Wednesday, April 15, 2026, including a fireside chat at 3:45 p.m. ET.
A live webcast of the presentation will be accessible via the company's Investor Relations website.
The Oncology Institute (NASDAQ: TOI) appointed Minh Merchant as Chief Legal Officer effective April 6, 2026. Ms. Merchant will oversee legal, regulatory, compliance and privacy functions to support TOI's scaling as a national oncology platform.
She brings more than two decades of healthcare legal experience, prior general counsel roles at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and a JD from UCLA School of Law.